Loading organizations...
VitalFlo develops a proactive respiratory care platform for diagnosing, monitoring, and managing lung health, especially for asthma. The system integrates a handheld spirometer with robust software and data, empowering healthcare providers to efficiently measure, track, and predict patient lung function. This enables timely interventions, ultimately improving overall patient care.
VitalFlo was founded in 2017 by Luke Marshall and James Dieffenderfer. Their insight stemmed from the critical need to improve respiratory care, specifically by helping clinicians reduce emergency room visits for asthmatic patients. Their work focuses on redefining chronic respiratory disease management through accessible and continuous patient monitoring.
The platform serves health systems, accountable care organizations, physician practices, and supports clinical research. VitalFlo’s mission is to significantly enhance respiratory care delivery by equipping providers with precise data and predictive insights. The company envisions a future where proactive management of respiratory conditions substantially improves patient well-being.
VitalFlo has raised $2.0M across 1 funding round.
VitalFlo has raised $2.0M in total across 1 funding round.
VitalFlo has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in July 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2021 | $2M Seed | — | Geekdom Fund, Scot Wingo | Announced |
VitalFlo has raised $2.0M in total across 1 funding round.
VitalFlo's investors include Geekdom Fund, Scot Wingo.
VitalFlo is a digital health company founded in 2017 in Raleigh, North Carolina, that developed a proactive respiratory care platform to transform pulmonary care by connecting patients and providers.[1][2][3] The platform provides in-office spirometry, remote patient monitoring, and data-driven clinical decision support, enabling healthcare providers to manage conditions like asthma and COPD across various settings, including medical groups, hospitals, ACOs, health systems, physician practices, clinical trials, and research.[1][2][3] Serving pulmonary patients, it addresses fragmented respiratory care by offering low-cost, handheld spirometry and at-home monitoring to improve outcomes and shift from reactive to proactive management; the company raised $3.7M before being acquired by Doktorconnect in May 2025, integrating its tools into a broader preventative health ecosystem.[1][2]
VitalFlo emerged in 2017 from Raleigh, NC, as a digital health startup focused on redefining asthma management and pulmonary care standards through accessible technology like low-cost handheld spirometers.[1][2][4] While specific founders are not detailed in available sources, the company quickly gained traction by developing a platform for in-office testing and remote monitoring, adopted by hospitals, medical groups, and ACOs to track pulmonary patients.[2][3] A pivotal moment came with its May 2025 acquisition by Doktorconnect, a Texas-based preventative health platform, which expanded VitalFlo's reach by embedding its respiratory solutions into holistic wellness tools for cardiovascular, metabolic, and other areas.[1][2]
VitalFlo rides the wave of digital health's shift toward preventative care, leveraging remote monitoring and IoT devices amid rising chronic respiratory diseases like asthma and COPD, exacerbated by post-pandemic telehealth adoption.[1][2] Its timing aligns with market forces favoring data-integrated platforms—FDA/CE-certified tech, value-based care models, and ACO expansions—that prioritize outcomes over volume, reducing hospital readmissions through proactive interventions.[2][3] By influencing pulmonary care standardization, VitalFlo contributes to the ecosystem's evolution, now amplified via Doktorconnect's holistic preventative suite, which broadens respiratory tools into multi-condition wellness.[1][2]
Post-acquisition, VitalFlo's platform will likely scale within Doktorconnect's ecosystem, enhancing unified preventative solutions with deeper respiratory integration and potential expansions into AI-enhanced predictions or global markets.[1][2] Trends like AI-driven personalization, wearable IoT proliferation, and regulatory pushes for remote care will propel its growth, evolving its influence from niche pulmonary innovator to key player in comprehensive chronic disease management. This positions it to sustain momentum in transforming "sick care" to proactive health, building on its foundational role in digital respiratory advancements.[2]
